Related Experiment Video

Updated: Jul 11, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

431

Anti-infectives in Pediatric Patients with Cystic Fibrosis: A Comprehensive Review of Population Pharmacokinetic

Aysenur Yaliniz1,2, Mehdi El Hassani3,4, Ana C Blanchard5,6

  • 1Laboratoire de Suivi Thérapeutique Pharmacologique et Pharmacocinétique, Faculty of Pharmacy, Université de Montréal, 2940 chemin de Polytechnique, Montreal, QC, H3T 1J4, Canada. aysenur.yaliniz@umontreal.ca.

Clinical Pharmacokinetics
|April 20, 2025
PubMed

Insights

This review summarizes anti-infective population pharmacokinetic (popPK) models for pediatric cystic fibrosis patients. Understanding these models improves antibiotic dosing and treatment optimization for lung infections.

Area of Science:

  • Pharmacology
  • Pediatric Pulmonology
  • Infectious Diseases

Background:

  • Pulmonary complications are a major cause of illness and death in children with cystic fibrosis (CF).
  • Optimizing anti-infective therapies is challenging due to altered pharmacokinetics and high variability in pediatric CF patients.
  • Population pharmacokinetic (popPK) models are crucial for understanding drug behavior in specific patient groups.

Purpose of the Study:

  • To systematically review and describe all anti-infective popPK models used in pediatric CF populations.
  • To identify commonly reported structural models and covariates.
  • To compare current clinical dosing with literature and guideline recommendations.

Main Methods:

  • A comprehensive literature search was conducted in the PubMed database up to August 2024.
  • Studies were selected based on predefined inclusion and exclusion criteria.
  • Data from 21 popPK models for eight different molecules were analyzed.

Main Results:

  • The review included 21 popPK models, covering eight molecules, including five key antibiotics for CF pulmonary infections.
  • All models utilized body composition and/or renal function as covariates.
  • Standard dosing regimens in the reviewed studies aligned with current guidelines and literature.

Conclusions:

  • This is the first comprehensive review of anti-infective popPK models in pediatric CF patients.
  • Enhanced pharmacokinetic parameter estimation and understanding variability sources can optimize antibiotic therapy.
  • Future research should monitor the impact of novel targeted therapies on CF management.

More Related Videos

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

798
Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

282

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...